Halozyme Therapeutics (HALO): Bets on Licensing Model to Drive Growth
Introduction
Halozyme Therapeutics is a biotechnology company that was co-founded in 1998 by Dr. Gregory Frost and subsequently listed in 2014.
Halozyme’s focus was on oncology therapies and drug delivery technologies based on its proprietary recombinant human hyaluronidase enzyme, rHuPH20, but following the failure of its oncology drug, the